by jtcir-auto | Apr 15, 2020 | Press Releases
CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic...
by jtcir-auto | Apr 15, 2020 | Press Releases
CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic...
by jtcir-auto | Apr 15, 2020 | Press Releases
– Presentation with live audio webcast on Thursday, April 23 at 10:00 AM ET, immediately followed by an interactive Q&A session -CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna...
by jtcir-auto | Apr 7, 2020 | Press Releases
– Modifications recommended for some key elements of planned safety and efficacy Study P02 — Modifications to the outline of Study P02 requested to ensure a harmonized global study protocol complying with requirements from EMA as well as FDA -CHARLESTON,...
by jtcir-auto | Apr 7, 2020 | Press Releases
– Modifications recommended for some key elements of planned safety and efficacy Study P02 — Modifications to the outline of Study P02 requested to ensure a harmonized global study protocol complying with requirements from EMA as well as FDA -CHARLESTON,...